Go Pro
NASDAQ:MBOT

Microbot Medical Q2 2026 Earnings Report

Microbot Medical logo
$1.36 -0.06 (-4.23%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$1.38 +0.01 (+1.10%)
As of 09/18/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Microbot Medical EPS Results

Actual EPS
-$0.08
Consensus EPS
-$0.08
Beat/Miss
Missed by -$0.00
One Year Ago EPS
N/A

Microbot Medical Revenue Results

Actual Revenue
$0.24 million
Expected Revenue
$0.13 million
Beat/Miss
Beat by +$108.00 thousand
YoY Revenue Growth
N/A

Microbot Medical Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
Tuesday, August 11, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

Microbot Medical's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Microbot Medical Earnings Headlines

Microbot Medical (NASDAQ:MBOT) Raised to "Sell" at Wall Street Zen
B. Riley Financial Begins Coverage on Microbot Medical (NASDAQ:MBOT)
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.tc pixel
See More Microbot Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Microbot Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Microbot Medical and other key companies, straight to your email.

About Microbot Medical

Microbot Medical (NASDAQ:MBOT) is a medical-device company focused on developing robotic and computer-assisted technologies for minimally invasive vascular procedures. The company’s primary product candidate is the LIBERTY Endovascular Robotic System, a compact, single-use system designed to enable physicians to remotely control the navigation and positioning of guidewires and catheters during endovascular interventions.

LIBERTY is intended to support procedures involving the peripheral and coronary vasculature while potentially reducing physician exposure to radiation and improving procedural control. Microbot Medical has described the system as a disposable platform designed to integrate into existing catheterization laboratories without requiring a large capital installation. The company continues to pursue regulatory and commercial development of its technology, and product availability is subject to applicable regulatory clearances.

Microbot Medical was established in Israel and conducts its research and development activities there, while pursuing opportunities in the United States and other international markets. The company is led by Harel Gadot, who serves as chairman, president and chief executive officer. Its shares trade on the Nasdaq Capital Market under the symbol MBOT.

View Microbot Medical Profile